Market revenue in 2023 | USD 80.0 million |
Market revenue in 2030 | USD 428.5 million |
Growth rate | 27.1% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.25% in 2023. Horizon Databook has segmented the Brazil cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
The robust growth & development in biologics and the rising biopharmaceutical market are expected to boost cell & gene therapy CDMO in the country. Moreover, the demand for cell and gene therapy CDMO in the country is growing as consumers increasingly seek effective biopharmaceutical formulations due to the growing burden of diseases.
The rising competition for drug development & approval is anticipated to increase the requirement for cell and gene therapy CDMO. Furthermore, government initiatives to reduce country’s pharmaceutical trade deficit and enhancement of domestic drug manufacturing are expected to boost the market.
For instance, in October 2023, Dipharma Francis S.R.L., a CDMO and major producer of APIs worldwide, announced that its manufacturing facility in Caronno Pertusella, close to Milan, Italy, has been granted the GMPcertification - Certificado de Boas Práticas de Fabricação (CBPF) - by Brazil's regulatory body Agência Nacional de Vigilância Sanitária (ANVISA). GMP certification from ANVISA enables Dipharma Francis S.R.L. to access the Brazilian pharmaceutical market, one of the largest in Latin America. This expands the company's market reach and potential client base
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Brazil cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account